Companies / Scinai Immunotherapeutics Ltd.

Scinai Immunotherapeutics Ltd.

Nasdaq: SCNIForeign ยท IFRSCIK 1611747JERUSALEM

Financials ยท FY2025

Revenue$1.31M
Net income$-8.31M
Total debt$382.0K
Cash$1.66M
Diluted EPS$-0.00
Shares outstanding1.31B

Ownership

1.31B shares outstanding ยท as of May 10, 2023
0.04%10%+ / strategic
Ownership
10%+ / strategic0.04%584,534
Institutions<0.01%81,949
Public float99.95%1,312,956,701

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 8

View all โ†’
Insider% of sharesShares
Ben-Or UriDirector
โ€”โ€”
Germain MarkDirector
โ€”โ€”
Green JayDirector
โ€”โ€”
Margolin YaelDirector
โ€”โ€”
Mark EladChief Operating Officer
โ€”โ€”
Moed Samuel JDirector
โ€”โ€”
Raviv AdiDirector
โ€”โ€”
Reichman AmirCEOChief Executive Officer ยท Director
โ€”โ€”

Institutional holders 7

View all โ†’
HolderValue% of shares
Citadel Advisors LLC$24.6K<0.01%
XTX Topco Ltd$19.4K<0.01%
UBS Group AG$1.2K<0.01%
Rhumbline Advisers$1.0K<0.01%
Northwestern Mutual Wealth Management Co$712<0.01%
Morgan Stanley$41<0.01%
Virtu Financial LLC$11<0.01%
InsidersInstitutions
What insiders are doing in this stock (Form 4).
DateActorActionSecurityValueShares ฮ”Position afterImpact
Jun 16, 2026Germain Mark
Director
GrantOrdinary Shares$0+120.0M
120,000,000
9.14% of shares
low

5%+ ownership events

Schedule 13D / 13G
FilerStance% of classSharesDate
Stone Daniel E.Passive13G/Aโ€”584,534โ€”

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
SCNIADREquity09073Q303BBG007TGL1R2